Resumen:
font face="AdvTT7b8c60ca.B" size="1">
In the present work, we investigated a first generation of a new dendrimer as candidate for intravenous (iv)
administration of a therapeutic compound (2(-(benzo[1,2-c] 1,2,5-oxadiazol-5(6)-yl (N-1-oxide) methylidene]-1-
methoxy methane hydrazide). This compound presents antichagasic activity but low water solubility. Guest–host
specific interactions results in good drug solubilization. These interactions can be controlled by varying the solution
pH, allowing drug deliverance. Interaction between dendrimer and human serum albumin (HSA), and the hemolytic
potential of dendrimer were evaluated. The dendrimer does not interact with blood proteins, i